Novocure releases data in a new indication; Apple's ResearchKit takes on Japan;

@FierceMedDev: ICYMI yesterday: Boston Sci receives FDA and CE mark approval of its thrombectomy catheter for deep vein thrombosis. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. Article | Follow @VarunSaxena2

@EmilyWFierce: $GILD: "Let's not fold to advocacy pressure in 2014." More from the WSJ | Follow @EmilyWFierce

> Novocure ($NVCR) disclosed positive, preliminary Phase II safety data in its trial of its Tumor Treating Fields therapy in patients with brain metastases originating from non-small cell lung cancer. More

> Early research studies using apps based on the Apple ResearchKit have started in Japan. Story

> Guided Therapeutics ($GTHP) said it has reached an agreement with the FDA on a plan for its PMA application for the LuViva Advanced Cervical Scan. More

Biotech News

@FierceBiotech: Q&A: Philips on what's next after the first year of HealthTech. More from FierceMedicalDevices | Follow @FierceBiotech

@JohnCFierce: Zafgen shares crash after second patient in pivotal obesity study dies. Report | Follow @JohnCFierce

@DamianFierce: Knicks Porzingis jersey not yet for sale so I'm just getting his name tattooed on my back as a placeholder. | Follow @DamianFierce

> Boehringer joins MD Anderson's cadre of cancer collaborators with pancreatic partnership. Report

> Ex-GSK cancer chief Paoletti scores $29M war chest for multiple myeloma startup Kesios. Article

> Outsmarting tumors: Biotech startup maestro Heyman fuels ORIC with $53M round. More

> MedDay misses endpoint in PhIII multiple sclerosis vision loss trial. Story

Pharma News

@FiercePharma: FDA approves Seqirus' Fluad, the first U.S. adjuvanted flu vaccine. FierceVaccines story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Bristol-Myers puts a blockbuster $142K price on new cancer med Empliciti. Article | Follow @CarlyHFierce

> Novo touts SGLT2-topping data for blockbuster Victoza. Story

> GSK jumps on the 'smart inhaler' bandwagon with Ellipta sensor deal. Report

> Americans point fingers at Big Pharma over dramatic drug price increases. Article

Biotech Research News

> UCLA scientist points to pregnancy hormone as a safe, simple MS therapy. Article

> Scripps team partially corrects impact of a cystic fibrosis mutation. More

> Rockefeller researchers study a new approach to controlling nicotine addiction. Story

> BRCA1 is back in the spotlight, this time for Alzheimer's disease. Report

> New class of antimicrobials may be highly potent against MRSA. Article

Vaccines News

> Parents may be misled by inaccurate HPV vaccine websites, report says. Item

> NIAID to bring Chikungunya vaccine into Phase II. Report

> Valneva's C. diff vaccine found to be 'highly immunogenic' in PhII. Article

> Sanofi, Shantha to supply polio vaccines for India's universal immunization scheme. More

> FDA approves Seqirus' Fluad, the first U.S. boosted flu vaccine. Story

Pharma Marketing News

> Novo Nordisk strikes back with SGLT2-beating data on Victoza. Story

> Study finds no shortage of misleading HPV vaccine websites. Item

> Amgen biosim advances toward battle with AbbVie's mega-selling Humira. Report

> Pfizergan headed for top of ad-spend leaderboard--and not just in pharma. Article

> Ex-Sanofi staffer adds new allegations to last year's kickback suit. More

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.